ECP 2022 Final Programme

Poster Sessions a Wednesday 110 Wednesday, 7 Sept PS-26 008 Prognostic value of tumour budding in urinary tract cancer: a meta-analysis Ruoyu Shi, Singapore M. Tan, G. Lim, L. Zeng, P. Tan 009 Enhanced TOLLIP expression confers poor prognosis in renal cell carcinoma Adam Kowalewski, Poland D. Jaworski, J. Borowczak, M. Maniewski, P. Antosik, J. Durślewicz, M. Smolińska, D. Grzanka, Ł. Szylberg 010 Role of epithelial-mesenchymal transition in clear cell renal cell carcinoma Jera Jeruc, Slovenia T. Čugura, S. Uhan, N. Zidar, E. Boštjančič 011 Spontaneous regression – scars of testicular germ cell tumours: association with clinicopathological features – institutional experience Bojana Jovanovic, Serbia B. Kovačević, I. Nikolić 012 Human epidermal growth factor receptor 2 (HER2) expression in urothelial carcinomas of the bladder Aasma Nalwa, India B. S. Arsha, P. Elhence, J. Naresh Bharti, M. Rao, G. Ram Choudhary 013 Two cases of primary intratesticular rhabdomyosarcoma Ihssan Elouarith, Morocco F. Zouaidia, A. Jahid, Z. Bernoussi, K. Znati 015 Intraductal carcinoma of the prostate in low-risk patients does not affect PSA failure and treatment decisions Remi Semba, Japan K. Uchida, T. Shiraishi, T. Onishi, T. Sasaki, T. Inoue, M. Watanabe 016 Papillary renal cell carcinoma (PRCC): a single institution archive review of morphological variability in the light of the new WHO 2022 classification Tiago André Sousa Oliveira, Portugal O. Hes 017 Pathological characterisation of Bosniak III and IV renal cysts Ricardo López Del Campo, Spain L. Rodríguez-Carunchio, K. Saez De Gordoa, S. Jiménez, C. Sebastià, T. Ajami, M. Musquera, I. Trias 018 P53 overexpression in prostate carcinoma Amen Dhaoui, Tunisia S. Ben Rejeb, M. Aloui, D. Aloui, R. Boulma 019 The potential of tumour microenviron- ment markers in the onset and progres- sion of prostate cancer Cristina-Anita Ionescu, Romania M. Aschie, G. Cozaru, M. Deacu, E. Matei, G. Baltatescu, A. Nicolau, I. Iorga, I. Burlacu, I. Dode, C. Orasanu, M. Enciu 020 Defining the most concordant basal and luminal urothelial markers using transcriptomic data Michelle Downes, Canada E. Olkhov-Mitsel, E. Slodkowska, Y. Yu, C. Sherman 021 Clinicopathologic assessment of MTAP status in muscle invasive urothelial carcinoma Michelle Downes, Canada E. Olkhov-Mitsel, E. Slodkowska 022 Neuroendocrine carcinomas of the urinary bladder: a large case series of a rare entity Roberta Maragliano, Italy G. Pini, L. Nicolini, C. Patriarca, M. Colecchia, F. Sessa, S. Uccella 023 Retrospective report-based review of kidney biopsies and resections with a focus on oncocytoma Michael Bonert, Canada N. Nikzad, I. El-Shinnawy, S. Salama, A. Kapoor